{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:52:34Z","timestamp":1776707554617,"version":"3.51.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72374179"],"award-info":[{"award-number":["72374179"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang University K. P. Chao\u2019s High Technology Development Foundation","award":["2022RC017"],"award-info":[{"award-number":["2022RC017"]}]},{"name":"Mega-Project of National Science and Technology for the 13th Five-Year Plan of China","award":["2018ZX10721102-003-006"],"award-info":[{"award-number":["2018ZX10721102-003-006"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"crossref","award":["K20210205"],"award-info":[{"award-number":["K20210205"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zhejiang Province Healthcare Innovation Talent Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-024-19670-9","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T13:02:48Z","timestamp":1723554168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Economic evaluation of hepatocellular carcinoma surveillance in chronic hepatitis B patients with virological remission"],"prefix":"10.1186","volume":"24","author":[{"given":"Kailu","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"6","key":"19670_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u2013606.","journal-title":"J Hepatol"},{"issue":"10","key":"19670_CR2","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1093\/annonc\/mdx342","volume":"28","author":"F Islami","year":"2017","unstructured":"Islami F, Chen W, Yu XQ, Lortet-Tieulent J, Zheng R, Flanders WD, et al. Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013. Ann Oncol. 2017;28(10):2567\u201374.","journal-title":"Ann Oncol"},{"issue":"Suppl 9","key":"19670_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.vaccine.2013.05.054","volume":"31","author":"F Cui","year":"2013","unstructured":"Cui F, Drobeniuc J, Hadler SC, Hutin YJ, Ma F, Wiersma S, et al. Review of hepatitis B surveillance in China: improving information to frame future directions in prevention and control. Vaccine. 2013;31(Suppl 9):79\u201384.","journal-title":"Vaccine"},{"issue":"1","key":"19670_CR4","first-page":"1","volume":"7","author":"P Song","year":"2013","unstructured":"Song P, Feng X, Zhang K, Song T, Ma K, Kokudo N, et al. Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: promoting the early detection of hepatocellular carcinoma in China. Biosci Trends. 2013;7(1):1\u20136.","journal-title":"Biosci Trends"},{"issue":"12","key":"19670_CR5","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1136\/gutjnl-2023-330691","volume":"72","author":"Z Liu","year":"2023","unstructured":"Liu Z, Lin C, Mao X, Guo C, Suo C, Zhu D, et al. Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people. Gut. 2023;72(12):2354\u201363.","journal-title":"Gut"},{"issue":"2","key":"19670_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cgh.2019.07.010","volume":"18","author":"JL Hou","year":"2020","unstructured":"Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a Randomized Trial in 24 countries. Clin Gastroenterol Hepatol. 2020;18(2):457\u201367.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"19670_CR7","first-page":"1109","volume":"60","author":"GV Papatheodoridis","year":"2011","unstructured":"Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece Cohort Study Gut. 2011;60(8):1109\u201316.","journal-title":"Greece Cohort Study Gut"},{"issue":"4","key":"19670_CR8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","volume":"62","author":"GV Papatheodoridis","year":"2015","unstructured":"Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62(4):956\u201367.","journal-title":"J Hepatol"},{"issue":"5","key":"19670_CR9","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/hep.23464","volume":"51","author":"J Simonetti","year":"2010","unstructured":"Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology. 2010;51(5):1531\u20137.","journal-title":"Hepatology"},{"issue":"15","key":"19670_CR10","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A, Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450\u201362.","journal-title":"N Engl J Med"},{"issue":"3","key":"19670_CR11","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M. American Association for the Study of Liver D, management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020\u20132.","journal-title":"Hepatology"},{"issue":"4","key":"19670_CR12","doi-asserted-by":"publisher","first-page":"e1001624","DOI":"10.1371\/journal.pmed.1001624","volume":"11","author":"AG Singal","year":"2014","unstructured":"Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624.","journal-title":"PLoS Med"},{"key":"19670_CR13","first-page":"100738","volume":"35","author":"S Zhang","year":"2023","unstructured":"Zhang S, Wang C, Liu B, Lu QB, Shang J, Zhou Y, et al. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation. Lancet Reg Health West Pac. 2023;35:100738.","journal-title":"Lancet Reg Health West Pac"},{"issue":"2","key":"19670_CR14","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1016\/S2214-109X(21)00517-9","volume":"10","author":"S Su","year":"2022","unstructured":"Su S, Wong WC, Zou Z, Cheng DD, Ong JJ, Chan P, et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. Lancet Glob Health. 2022;10(2):e278\u201387.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"19670_CR15","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jhep.2022.12.007","volume":"78","author":"WM Choi","year":"2023","unstructured":"Choi WM, Yip TC, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, et al. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: individual patient data meta-analysis. J Hepatol. 2023;78(3):534\u201342.","journal-title":"J Hepatol"},{"issue":"1","key":"19670_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver, EASL Clinical Practice Guidelines","year":"2018","unstructured":"European Association for the Study of the Liver, EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol"},{"issue":"4","key":"19670_CR17","first-page":"367","volume":"30","author":"National Health Commission of the People\u2019s Republic of China Medical Administration hospital Authority","year":"2022","unstructured":"National Health Commission of the People\u2019s Republic of China Medical Administration hospital Authority. Guidelines for diagnosis and treatment of primary liver cancer in China (2022 edition). Chin J Hepatol. 2022;30(4):367\u201388.","journal-title":"Chin J Hepatol"},{"issue":"7","key":"19670_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","volume":"4","author":"PA Revill","year":"2019","unstructured":"Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545\u201358.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"19670_CR19","unstructured":"Macrotrends. accessed Dec 19, China life expectancy 1950\u20132022. https:\/\/www.macrotrends.net\/countries\/CHN\/china\/life-expectancy (2022)."},{"issue":"1","key":"19670_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic evaluation reporting standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Health. 2022;25(1):3\u20139.","journal-title":"Value Health"},{"issue":"1","key":"19670_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/liv.15085","volume":"42","author":"CF Huang","year":"2022","unstructured":"Huang CF, Jang TY, Jun DW, Ahn SB, An J, Enomoto M, et al. On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. Liver Int. 2022;42(1):59\u201368.","journal-title":"Liver Int"},{"issue":"1","key":"19670_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","volume":"158","author":"TC Yip","year":"2020","unstructured":"Yip TC, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL. Tenofovir is Associated with Lower Risk of Hepatocellular Carcinoma Than Entecavir in patients with chronic HBV infection in China. Gastroenterology. 2020;158(1):215\u201325.","journal-title":"Gastroenterology"},{"issue":"1","key":"19670_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/liv.15027","volume":"42","author":"M Toy","year":"2022","unstructured":"Toy M, Hutton D, McCulloch K, Romero N, Revill PA, Penicaud MC, et al. The price tag of a potential cure for chronic hepatitis B infection: a cost threshold analysis for USA, China and Australia. Liver Int. 2022;42(1):16\u201325.","journal-title":"Liver Int"},{"issue":"5","key":"19670_CR24","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep.26301","volume":"58","author":"GL Wong","year":"2013","unstructured":"Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58(5):1537\u201347.","journal-title":"Hepatology"},{"issue":"10","key":"19670_CR25","doi-asserted-by":"publisher","first-page":"e154833","DOI":"10.1172\/JCI154833","volume":"132","author":"WM Choi","year":"2022","unstructured":"Choi WM, Kim GA, Choi J, Han S, Lim YS. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B. J Clin Invest. 2022;132(10):e154833.","journal-title":"J Clin Invest"},{"issue":"Suppl 2","key":"19670_CR26","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1002\/lt.22365","volume":"17","author":"V Mazzaferro","year":"2011","unstructured":"Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17(Suppl 2):S44\u201357.","journal-title":"Liver Transpl"},{"issue":"1","key":"19670_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2214\/AJR.18.20341","volume":"213","author":"PH Lima","year":"2019","unstructured":"Lima PH, Fan B, Berube J, Cerny M, Olivie D, Giard JM, et al. Cost-Utility Analysis of Imaging for Surveillance and Diagnosis of Hepatocellular Carcinoma. AJR Am J Roentgenol. 2019;213(1):17\u201325.","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"19670_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/jvh.12482","volume":"23","author":"S Zhang","year":"2016","unstructured":"Zhang S, Ma Q, Liang S, Xiao H, Zhuang G, Zou Y, et al. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. J Viral Hepat. 2016;23(3):202\u201310.","journal-title":"J Viral Hepat"},{"issue":"11","key":"19670_CR29","first-page":"673","volume":"10","author":"MY Bertram","year":"2021","unstructured":"Bertram MY, Lauer JA, Stenberg K, Edejer TTT. Methods for the Economic Evaluation of Health Care Interventions for Priority Setting in the Health System: an Update from WHO CHOICE. Int J Health Policy Manag. 2021;10(11):673\u20137.","journal-title":"Int J Health Policy Manag"},{"key":"19670_CR30","volume-title":"China statistical yearbook 2021","author":"Department of Population and Employment Statistics, National Bureau of Statistics of China","year":"2021","unstructured":"Department of Population and Employment Statistics, National Bureau of Statistics of China. China statistical yearbook 2021. Beijing: China Statistics; 2021."},{"issue":"2","key":"19670_CR31","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the study of Liver diseases. Hepatology. 2018;68(2):723\u201350.","journal-title":"Hepatology"},{"issue":"4","key":"19670_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317\u201370.","journal-title":"Hepatol Int"},{"issue":"9","key":"19670_CR33","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","volume":"17","author":"H Farhang Zangneh","year":"2019","unstructured":"Farhang Zangneh H, Wong WWL, Sander B, Bell CM, Mumtaz K, Kowgier M, et al. Cost Effectiveness of Hepatocellular Carcinoma Surveillance after a sustained Virologic response to therapy in patients with Hepatitis C virus infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2019;17(9):1840\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"19670_CR34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","volume":"72","author":"AG Singal","year":"2020","unstructured":"Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250\u201361.","journal-title":"J Hepatol"},{"issue":"10127","key":"19670_CR35","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J, Hepatocellular carcinoma. Lancet. 2018;391(10127):1301\u201314.","journal-title":"Lancet"},{"issue":"8","key":"19670_CR36","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/liv.15321","volume":"42","author":"H Cheng","year":"2022","unstructured":"Cheng H, Liu S, Luo S, Chan P, Chen Z, Le LV, et al. Uptake of hepatitis B antiviral treatment: a panel data analysis of 31 provinces in China (2013\u20132020). Liver Int. 2022;42(8):1762\u20139.","journal-title":"Liver Int"},{"issue":"8","key":"19670_CR37","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/jvh.13711","volume":"29","author":"G Marley","year":"2022","unstructured":"Marley G, Seto WK, Yan W, Chan P, Tucker JD, Tang W, et al. What facilitates hepatitis B and hepatitis C testing and the role of stigma among primary care patients in China? J Viral Hepat. 2022;29(8):637\u201345.","journal-title":"J Viral Hepat"},{"issue":"2","key":"19670_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3350\/cmh.2023.0412","volume":"30","author":"S Shan","year":"2024","unstructured":"Shan S, Zhao X, Jia J. Comprehensive approach to controlling chronic hepatitis B in China. Clin Mol Hepatol. 2024;30(2):135\u201343.","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"19670_CR39","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1002\/hep.26138","volume":"56","author":"M Sherman","year":"2012","unstructured":"Sherman M. Whither hepatocellular carcinoma screening? Hepatology. 2012;56(6):2412\u20134.","journal-title":"Hepatology"},{"key":"19670_CR40","doi-asserted-by":"crossref","unstructured":"Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology 2011, 54(6): 1998\u20132004.","DOI":"10.1002\/hep.24581"},{"issue":"7","key":"19670_CR41","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jama.2017.19872","volume":"320","author":"JJ Kim","year":"2018","unstructured":"Kim JJ, Burger EA, Regan C, Sy S. Screening for Cervical Cancer in Primary Care: a decision analysis for the US Preventive Services Task Force. JAMA. 2018;320(7):706\u201314.","journal-title":"JAMA"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-19670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-19670-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-19670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T13:03:30Z","timestamp":1723554210000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-19670-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["19670"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-19670-9","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2202"}}